Based on the encouraging activity of Tazemetostat against B‐cell lymphomas in phase I of NCT01897571, investigators aimed to investigate further whether specific lymphoma entities would exhibit enhanced efficacy and whether EZH2 mutational status would influence treatment sensitivity. Here, EZH2 is linked to lymphoma.